Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Yutaka Fujiwara, MD, PhD"'
Autor:
Sai-Hong Ignatius Ou, MD, PhD, Yutaka Fujiwara, MD, PhD, Alice T. Shaw, MD, PhD, Noboru Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Frank Fan, MD, Yuki Hao, MSc, Yanfei Gao, MSc, Pasi A. Jänne, MD, Takashi Seto, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100108- (2021)
Introduction: Taletrectinib (AB-106/DS-6051b) is an oral, potent selective ROS1 and pan-NTRK tyrosine kinase inhibitor (TKI). Preclinically, taletrectinib has activity against ROS1 G2032R solvent-front mutation. Methods: Patients with ROS1+ NSCLC enr
Externí odkaz:
https://doaj.org/article/64233781feae4b948e90754ce61ce9a4